Securities Analyst Recommendations: XBiotech Inc. (XBIT), BioXcel Therapeutics, Inc. (BTAI)

XBiotech Inc. (NASDAQ:XBIT) tinted gains of +3.02% (+0.28 points) to US$9.54. The volume of 0.2 Million shares climbed down over an trading activity of 158.81 Million shares. EPS ratio determined by looking at last 12 month figures is -0.65. Over the same time span, the stock marked US$10.7 as its best level and the lowest price reached was US$2.13. The corporation has a market cap of US$342.58 Million.

XBiotech Inc. (NASDAQ:XBIT)’s earnings per share has been growing at a -14.7 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -41.4 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 13.2 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is worth US$134.08 Million and has recently fallen -5.04% to US$8.47. The latest exchange of 0.08 Million shares is below its average trading activity of 157.54 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$14.79 while the mean 12-month price target for the shares is US$18.2.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.89, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 20.6%, it carries an earnings per share ratio of -1.04.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.6.